

*Lilly*

1876

**150**

2026

**YEARS OF MEDICINE**

A scientist with a beard and glasses, wearing a white lab coat, is working in a laboratory. He is holding a small vial and looking at a piece of equipment. In the background, there is a computer monitor displaying a graph. The scene is dimly lit, with the primary light source coming from the monitor and some equipment lights.

Eli Lilly and Company

# Q1 2026 Earnings Call

*Lilly*



# Agenda

## Introduction and Key Events

David Ricks, Chair and Chief Executive Officer

---

## Q1 2026 Financial Results

Lucas Montarce, Chief Financial Officer

---

## R&D Update

Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer

---

## Question & Answer Session

---

# Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; the implementation of our voluntary agreement with the U.S. government related to drug pricing and access; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. Numbers in this presentation may not add due to rounding.

**The company undertakes no duty to update forward-looking statements except as required by applicable law.**

# Q1 2026 Progress on Strategic Deliverables

## Broaden Impact on Cardiometabolic Health

- Incretin revenue grew 90%
- Foundayo now launched in the U.S. for obesity
- Positive Phase 3 data for Foundayo and retatrutide
- Initiated Phase 3 studies with eloralintide

## Expand Presence in Other Therapeutic Areas

- 160% Key Product revenue growth in Immunology, Oncology and Neuroscience
- Positive topline data for Ebglyss, Jaypirca and Taltz +Zepbound studies
- Initiated Phase 3 studies with brenipatide and sofetabart mipitecan

## Invest to Drive Future Growth

- Announced new manufacturing site in Lehigh Valley, PA
- Began production at Kenosha County, Wisconsin manufacturing site
- Announced acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, Ajax Therapeutics

**\$19.8B** ↑ 56%

**Q1 WORLDWIDE REVENUE**

**+110%**

**KEY PRODUCT REVENUE GROWTH**

**\$8.55** ↑ 156%

**NON-GAAP EPS**

Growth rates reflect change vs Q1 2025

The Company currently defines Key Products as Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound. Effective Q1 2026, Verzenio is excluded from Key Products.

Incretins include Mounjaro, Zepbound and Trulicity



# Q1 2026 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
Total revenue	\$19,799	\$ -	\$19,799	56%
Gross margin	81.9%	0.7pp	82.6%	-0.9pp
Total operating expense	\$7,307	\$(279)	\$7,028	4%
Operating income	\$8,915	\$407	\$9,322	142%
Other income (expense)	\$(65)	\$(79)	\$(144)	66%
Effective tax rate	16.4%	0.1pp	16.5%	-3.7pp
Net income	\$7,396	\$267	\$7,663	155%
EPS	\$8.26	\$0.29	\$8.55	156%
<i>Acquired IPR&amp;D Charge per share<sup>1</sup></i>	\$0.52	\$ -	\$0.52	-70%

<sup>1</sup> Acquired IPR&D (in-process research and development) charge of \$584 million (pre-tax).

<i>Performance Margin<sup>2</sup></i>	48.0%	50.0%	+7.4pp
---------------------------------------	-------	-------	--------

<sup>2</sup> The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue. Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 23.



# Price/Rate/Volume Effect on Revenue

Dollars in millions

Q1 2026

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	\$12,119	(7)%	-	49%	43%	43%
Europe	\$3,646	5%	16%	32%	53%	37%
Japan	\$571	2%	(0)%	40%	42%	42%
China <sup>1</sup>	\$693	NM	2%	NM	54%	52%
Rest of world	\$2,771	(4)%	10%	172%	178%	168%
<b>Total revenue</b>	<b>\$19,799</b>	<b>(13)%</b>	<b>4%</b>	<b>65%</b>	<b>56%</b>	<b>52%</b>


Dollars in millions. Numbers may not add due to rounding. CER= price change + volume change; NM = not meaningful

<sup>1</sup> China price and volume driven by inclusion of Mounjaro on National Reimbursed Drug List for Type 2 Diabetes, with lower price and higher volume vs. Q1 2025



# Q1 2026 Update on Key Products

\$13.4B Key Product revenue, representing 68% of Q1 2026 revenue



The Company currently defines Key Products as Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound. Effective Q1 2026, Verzenio is excluded from Key Products.



2026 Q1 Earnings

## Cardiometabolic Health

Mounjaro U.S. TRx SOM grew to 51%<sup>1</sup>

Zepbound Q1 2026 sales of \$4.2B, +80% vs. Q1 2025

## Immunology

Ebglyss Q1 2026 sales of \$145M, +141% vs Q1 2025

## Oncology

Jaypirca Q1 2026 sales of \$165M, +79% vs Q1 2025

Inluriyo Q1 2026 sales of \$35M

## Neuroscience


Kisunla Q1 2026 sales of \$124M

# +160%

Key Product revenue growth in  
Immunology, Oncology & Neuroscience

<sup>1</sup> Source: U.S. type 2 diabetes incretin analogs market, IQVIA weekly NPA total prescriptions weekly data March 27, 2026

# U.S. Incretin Analogs Market



**+30%**

Q1 2026 U.S. market growth


**60.1%**

Lilly share of market



Source: IQVIA weekly NPA total prescriptions, weekly data 3/27/2026  
 Rolling 4 week SOM. Incretin analogs market includes injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

# International Incretin Analogs Market



**+77%**  
Q1 2026 market growth

**53.2%**  
Lilly share of market



2026 Q1 Earnings

Growth rate: Jan/Feb 2026 vs. Jan/Feb 2025  
 Data source: IQVIA GMI Agent AI, MIDAS Monthly accessed 4/29/2026  
 US MNF: Sales in US dollars at the exchange rate in effect at the time of sale;  
 MNF: Wholesaler purchase price and manufacturer's selling price  
 Market basket: Bydureon/Byetta, Lyxumia, Victoza, Ozempic, Trulicity, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound  
 Geography: Worldwide excluding USA and Puerto Rico

# Foundayo U.S. launch off to a strong start



**80%+** of Foundayo prescriptions are new incretin patients



Broadly available in retail April 9



12+ major telehealth platforms offering Foundayo, approximately 35% of launch volume



Commercial access confirmed at 2/3 major PBMs by mid-May  
Medicare access through GLP-1 Bridge program July 1




HCP digital engagement live from launch  
Salesforce active April 17, sampling begins in coming weeks



Full-scale consumer promotion beginning in Q3

# Q1 2026 Capital Allocation

\$ in billions



<sup>1</sup> After tax

<sup>2</sup> Includes development milestones, closed acquisitions and cash outflows associated with equity investments

# 2026 Guidance (Non-GAAP)

	Prior	Updated	Comments
Revenue <sup>1</sup>	\$80.0 – \$83.0 billion	\$82.0 – \$85.0 billion	Strong underlying business performance; midpoint growth 28% year over year
Performance Margin <sup>2</sup>	46.0% – 47.5%	47.0% – 48.5%	Increased to reflect updated revenue expectations
Tax Rate	Approximately 18-19%	Unchanged	
Earnings per share <sup>3</sup>	\$33.50 – \$35.00	\$35.50 – \$37.00	Increased to reflect updated revenue expectations

<sup>1</sup> GAAP measure

<sup>2</sup> The Company defines Performance Margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue.


<sup>3</sup> 2026 assumes shares outstanding of approximately 895 million

Note: See slides 23 and 24 for additional Non-GAAP information.

FX assumptions of 1.16 (Euro), 153 (Yen) and 7.1 (Yuan)

# Foundayo ACHIEVE-4 Results

## ACHIEVE-4 Select Hazard Ratios (95% CI)



## Key Highlights:

Demonstrated cardiovascular safety and durable efficacy

16% lower risk of MACE-4 events<sup>4</sup>

23% lower risk of MACE-3 events<sup>4</sup>

No hepatic safety signal observed in this advanced disease population

<sup>1</sup> Time to first event analysis using Cox proportional hazard model


<sup>2</sup> Boundary for non-inferiority statistical significance < 1.8

<sup>3</sup> Pre-planned analysis not multiplicity controlled for type-1 error

<sup>4</sup> vs. insulin glargine

# Retatrutide TRANSCEND-T2D-1 Results

## HbA1c and Body Weight Change at 40 Weeks<sup>1</sup>



<sup>1</sup> Efficacy estimand

### Key Highlights:


A1C reduction up to 2.0%

Clinically meaningful improvements in key cardiovascular risk factors


Discontinuation due to adverse events 5% or less across arms

# Ebglyss ADorable-1 Topline Results

## IGA 0,1 at Week 16



## EASI 75 at Week 16



## Key Highlights:

Superior efficacy vs. placebo in patients aged 6 months to < 18 years

EASI-75 achieved by 2.9x more Ebglyss participants vs. placebo

U.S. and global regulatory submissions planned in 2026

Safety consistent with the known Ebglyss profile, with no injection site pain

\*\*\* P value < 0.001. Rescue medication (high potency TCS and systemic therapy) use considered as non-responders

Overall intent-to-treat population includes participants aged 6 months to < 18 years

IGA (0,1)=Investigator's Global Assessment (Clear or Almost Clear); EASI 75 = reduction of  $\geq 75\%$  in Eczema Area and Severity Index; PBO=placebo;

TCS=topical corticosteroid

# Jaypirca Positive Data Across CLL Treatment Settings

	Treatment-Naïve	R/R BTKi Naïve	R/R Post-cBTKi	
✓ BRUIN CLL-313 Jaypirca vs. BR	<b>80%</b> PFS risk reduction vs BR <i>U.S. Regulatory Review</i>			<b>Continuous Dosing</b>
✓ BRUIN CLL-314 Jaypirca vs. Ibrutinib	<b>76%</b> PFS risk reduction vs ibrutinib <sup>1</sup> <i>U.S. Regulatory Review</i>	<b>27%</b> PFS risk reduction vs ibrutinib <sup>1</sup> <i>U.S. Regulatory Review</i>		
✓ BRUIN CLL-321 Jaypirca vs. IdelaR or BR			<b>46%</b> PFS risk reduction vs IdelaR or BR <i>U.S. Full Approval</i>	
✓ BRUIN CLL-322 Jaypirca + VenR vs. VenR		<b>Topline Positive</b> <i>Planned Submission</i>	<b>Topline Positive</b> <i>Planned Submission</i>	<b>Time-Limited Regimen</b>

Most CLL patients' disease courses are managed by one or two lines of therapy – Jaypirca could become a foundational therapy in CLL as a continuously dosed monotherapy in either line, or a time-limited combination in second line

CLL = chronic lymphocytic leukemia; R/R = relapsed / refractory; BTKi = Bruton tyrosine kinase inhibitor; cBTKi = covalent Bruton tyrosine kinase inhibitor; BR = bendamustine + rituximab; IdelaR = idelalisib + rituximab; VenR = venetoclax + rituximab; PFS = progression free survival

<sup>1</sup> PFS immature at time of readout and % of Treatment-Naïve patients and R/R BTK Naïve patients in CLL-314 was approximately 34% and 66% respectively



# Lilly Select Pipeline

April 28, 2026

NME

NILEX / Other

REMOVAL

ADDITION OR MILESTONE ACHIEVED

UPDATES SINCE February 3, 2026

BRENIPATIDE <i>Opioid Use Disorder</i>	BRENIPATIDE <i>Schizophrenia</i>	
TIRZEPATIDE <i>Higher Doses</i>	ZOTEMTEGRAST + MIRIKIZUMAB <i>UC</i>	ZOTEMTEGRAST (INTEGRIN $\alpha 4\beta 7$ ) <i>CD</i>
BRENIPATIDE <i>Tobacco Use Disorder</i>	ELTREKIBART <i>Ulcerative Colitis</i>	GBA1 GENE THERAPY <i>Gaucher Disease Type 1</i>
NLRP3 INH II (VTX2735) <i>Recurrent Pericarditis</i>	BRENIPATIDE <i>Asthma</i>	BRENIPATIDE <i>Bipolar Disorder</i>
AT2R ANTAGONIST <i>Pain</i>	NAV 1.8 INH (SM) <i>Pain</i>	NLRP3 INH (VTX3232) <i>Inflammatory Disorders</i>
SOLBINSIRAN <i>Severe Hypertriglyceridemia</i>	TURIGROBART (EPIREGULIN Ab) <i>Pain</i>	ZOTEMTEGRAST (INTEGRIN $\alpha 4\beta 7$ ) <i>UC</i>
NISOTIROSTIDE <i>Diabetes</i>	OTOF GENE THERAPY <i>Hearing Loss</i>	SIMEPDEKINRA <i>Psoriasis</i>
MACUPATIDE <i>Obesity</i>	MEVIDALEN <i>Symptomatic AD</i>	NAPERIGLIPRON <i>Obesity</i>
GBA1 GENE THERAPY <i>Parkinson's Disease</i>	GIPR AGONIST LA <i>CINV</i>	GS INSULIN RECEPTOR AGONIST <i>Diabetes</i>
AIPL1 GENE THERAPY <i>LCA4</i>	BIMAGRUMAB <i>Obesity</i>	ELTREKIBART <i>Hidradenitis Suppurativa</i>

PHASE 2

OCADUSERTIB  
*Rheumatoid Arthritis*

ELORALINTIDE <i>Osteoarthritis Pain</i>	SOFETABART MIPITECAN <i>PSOC</i>		
BARICITINIB <i>Type 1 Diabetes</i>	BRENIPATIDE <i>Major Depressive Disorder</i>	ELORALINTIDE INCRETIN ADD-ON <i>Obesity</i>	ELORALINTIDE <i>Obstructive Sleep Apnea</i>
SELPERCATINIB <i>Adjuvant RET+ NSCLC</i>	TIRZEPATIDE <i>MASLD</i>	TIRZEPATIDE <i>Morbidity and Mortality in Obesity</i>	TIRZEPATIDE <i>Type 1 Diabetes</i>
RETATRUTIDE <i>Chronic Low Back Pain</i>	RETATRUTIDE <i>CV / Renal Outcomes</i>	RETATRUTIDE <i>Diabetes</i>	RETATRUTIDE <i>MASLD</i>
ORFORGLIPRON <i>Peripheral Artery Disease</i>	ORFORGLIPRON <i>Stress Urinary Incontinence</i>	PIRTOBRUTINIB <i>R/R CLL Combination</i>	PIRTOBRUTINIB <i>R/R MCL Monotherapy</i>
ORFORGLIPRON <i>Cardiovascular Outcomes</i>	ORFORGLIPRON <i>Hypertension</i>	ORFORGLIPRON <i>Obstructive Sleep Apnea</i>	ORFORGLIPRON <i>Osteoarthritis Pain</i>
MIRIKIZUMAB + TIRZEPATIDE <i>UC</i>	OLOMORASIB 1L KRAS <i>G12C+ NSCLC (PD-L1 high)</i>	OLOMORASIB Adj KRAS <i>G12C+ NSCLC (resected)</i>	OLOMORASIB Adj KRAS <i>G12C+ NSCLC (unresected)</i>
IXEKIZUMAB + TIRZEPATIDE <i>Psoriasis</i>	LEBRIKIZUMAB <i>AR (perennial allergens)</i>	LEBRIKIZUMAB <i>CRSwNP</i>	MIRIKIZUMAB + TIRZEPATIDE <i>CD</i>
SOFETABART MIPITECAN <i>PROC</i>	DONANEMAB <i>Cognitively Unimpaired AD</i>	IMLUNESTRANT <i>Adjuvant Breast Cancer</i>	IXEKIZUMAB + TIRZEPATIDE <i>PsA</i>
MUVALAPLIN <i>ASCVD</i>	OLOMORASIB 1L KRAS <i>G12C+ NSCLC (All PD-L1)</i>	REMTNETUG <i>Cognitively Unimpaired / MCI due to AD</i>	RETATRUTIDE <i>Obesity, OA, OSA</i>
BRENIPATIDE <i>Alcohol Use Disorder</i>	ELORALINTIDE <i>Obesity</i>	IXO-VEC <i>wet Age-Related Macular Degeneration</i>	LEPODISIRAN <i>ASCVD</i>

PHASE 3

ORFORGLIPRON  
*Obesity*

APPROVED

TIRZEPATIDE  
*Cardiovascular Outcomes*

PIRTOBRUTINIB  
*1L CLL Monotherapy*


ORFORGLIPRON  
*Diabetes*

INSULIN EFSITORA ALFA  
*Diabetes*

REG REVIEW



# Potential Key Events 2026

 New since last update

## Phase 3 Initiations

- ⊙ Eloralintide for obesity or overweight
- ⊙ Eloralintide incretin add-on for obesity or overweight
- ⊙ Eloralintide for OA knee pain
- ⊙ Eloralintide for OSA and obesity or overweight
- ⊙ Orforglipron for peripheral artery disease
- Vepugratinib for 1L metastatic urothelial cancer
- Tersolisib for advanced breast cancer
- ⊙ Sofetabart Mipitecan for platinum-resistant ovarian cancer
- ⊙ Sofetabart Mipitecan for platinum-sensitive ovarian cancer
- ⊙ Brenipatide for major depressive disorder
- ⊙ Baricitinib for type 1 diabetes

## Phase 3 Data Disclosures

- ⊙ Ixekizumab and tirzepatide for psoriatic arthritis and obesity or overweight
- ⊙ Ixekizumab and tirzepatide for psoriasis and obesity or overweight
- ⊙ Orforglipron for type 2 diabetes [ACHIEVE-4]
- Orforglipron for obstructive sleep apnea
- Retatrutide for obesity or overweight [TRIUMPH 1/2/3]
- Retatrutide for type 2 diabetes [TRANSCEND-T2D 1 ⊙/2/3]
- ⊙ Lebrikizumab for pediatric atopic dermatitis
- ⊙ Pirtobrutinib for R/R CLL combination [BRUIN-322]

## Regulatory Submissions

- Orforglipron for type 2 diabetes [US/ EU ⊙/J]
- Orforglipron for obstructive sleep apnea and obesity or overweight
- Retatrutide for overweight or obesity
- Retatrutide for obstructive sleep apnea and obesity or overweight
- Retatrutide for osteoarthritis pain of the knee and obesity or overweight
- Pirtobrutinib for R/R CLL combination
- Lebrikizumab for pediatric atopic dermatitis

## Regulatory Actions

- ⊙ Zepbound KwikPen [US]
- Tirzepatide for cardiovascular outcomes
- ⊙ Orforglipron for overweight or obesity [US]
- Orforglipron for type 2 diabetes
- Insulin efsitora alfa for type 2 diabetes
- Pirtobrutinib for 1L CLL
- Lebrikizumab maintenance dosing once every 8 weeks

# Q1 2026 Summary

↑ **56%**  
Revenue growth

**\$8.55**  
Non-GAAP EPS

**1** New approved  
Lilly Medicine

**Foundayo™**  
(orforglipron)

**5** Positive Phase 3  
Clinical Trials

**6** New Phase 3  
Programs

**4** Acquisitions  
announced

**ORNA** **kelonia**  
**CENTESSA** **Ajax**  
PHARMACEUTICALS THERAPEUTICS

Increased full year revenue guidance

**\$82.0B - \$85.0B**

Increased non-GAAP EPS guidance

**\$35.50 - \$37.00**

**Broaden Impact on  
Cardiometabolic Health**

**Expand Presence in Other  
Therapeutic Areas**

**Invest to Drive  
Future Growth**

**Save the Date:** Investment Community Meeting | December 7, 2026

# Supplemental Slides

# 2026 Income Statement -- Reported

Dollars in millions; except per share data

	Q1 2026	Change
Total revenue	\$19,799	56%
Gross margin	81.9%	-0.6pp
Total operating expense*	\$7,307	7%
Operating income	\$8,915	141%
Operating margin	45.0%	16.0pp
Other income (expense)	\$(65)	(73)%
Effective tax rate	16.4%	-3.8pp
Net income	\$7,396	168%
EPS	\$8.26	170%

\* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)

# EPS Reconciliation

	Q1 2026	Q1 2025	% Change
Earnings per share (reported)	\$8.26	\$3.06	170%
Asset impairment, restructuring and other special charges	0.25	0.03	NM
Amortization of intangible assets	0.11	0.11	0%
Net losses (gains) on investments in equity securities	(0.07)	0.13	NM
Earnings per share (Non-GAAP)	\$8.55	\$3.34	156%
Acquired IPR&D	\$0.52	\$1.72	(70)%

Numbers may not add due to rounding; see slide 25 for more details on these adjustments; NM = not meaningful

# Q1 Non-GAAP Adjustments

## Q1 2026 non-GAAP information has been adjusted to exclude:


- Asset impairment, restructuring and other special charges totaling \$279 million (pre-tax), or \$0.25 per share (after-tax)
- Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$128 million (pre-tax), or \$0.11 per share (after-tax)
- Net gains on investments in equity securities totaling \$79 million (pre-tax), or (\$0.07) per share (after-tax)

## Q1 2025 non-GAAP information has been adjusted to exclude:


- Asset impairment, restructuring and other special charges, primarily the impairment of Prevail and POINT intangible assets, totaling \$35 million (pre-tax), or \$0.03 per share (after-tax)
- Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$123 million (pre-tax), or \$0.11 per share (after-tax)
- Net losses on investments in equity securities totaling \$152 million (pre-tax), or \$0.13 per share (after-tax)

# Q1 2026 Mounjaro Sales Increased \$4.8B

**U.S. sales were \$4.2 billion**  
**International sales were \$4.4 billion**



## U.S. TRX SOM and Market Volume




Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2026; RA = rolling average  
 TRx data is representative of the Incretin Analogs - type 2 diabetes market




# Q1 2026 Zepbound Sales Increased \$1.8B

U.S. sales were \$4.1 billion<sup>1</sup>



<sup>1</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. International sales were \$26 million in Q1 2026

## U.S. TRX SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2026; RA = rolling average  
TRx data is representative of the branded incretin analogs – OMM market

# Select Trials – Abemaciclib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT03155997<sup>1</sup></b>	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival	Mar 2020	May 2029
<b>NCT05169567</b>	Breast Cancer	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)	3	368	Progression-Free Survival (PFS)	Feb 2024	Dec 2027

<sup>1</sup> Also lists NSABP Foundation Inc

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Baricitinib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07222332</b>	Type 1 Diabetes	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	3	300	Change from Baseline in C-peptide Area Under the Curve (AUC)	Jul 2028	Jul 2028
<b>NCT07222137</b>	Type 1 Diabetes	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)	3	150	Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes	Jul 2031	Jul 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Brenipatide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07412756</b>	Major Depressive Disorder	A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1)	3	1000	Time to Relapse as Measured by Number of Days from Randomization to Date Participant Meets Any Relapse Criterion of MDD	Feb 2028	Feb 2028
<b>NCT07219966</b>	Alcohol Use Disorder	A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
<b>NCT07219953</b>	Alcohol Use Disorder	A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
<b>NCT07420283</b>	Opioid Use Disorder	A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1)	2	465	Percentage of weeks abstinence from opioid use defined by both negative urine drug screen (UDS) and no self-report of opioid use based on timeline follow back (TLFB) Achievement of >=80% weeks of abstinence from opioid use defined by both negative UDS and no self-report of opioid use based on TLFB	Mar 2028	Mar 2028
<b>NCT07286175</b>	Bipolar Disorder	A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)	2	400	Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion	Nov 2027	Nov 2027
<b>NCT07223840</b>	Tobacco Use Disorder	A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1)	2	222	Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips	Feb 2027	Feb 2027
<b>NCT07410507</b>	Schizophrenia	A Study of Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1)	2	450	Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index $\geq 25.0$ Kilograms per Meter Squared ( $\text{kg}/\text{m}^2$ )	Nov 2027	Nov 2027
<b>NCT07219173</b>	Asthma	A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma	2	531	Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment	Apr 2028	Jun 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Donanemab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT04437511</b>	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)	Apr 2023	Nov 2028
<b>NCT05026866</b>	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2996	Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR)	Nov 2027	Nov 2027
<b>NCT05508789</b>	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2028	Jul 2028
<b>NCT05738486</b>	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	1175	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Eloralintide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07321886</b>	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1)	3	1980	Percent Change from Baseline in Body Weight	Mar 2028	Jul 2030
<b>NCT07282600</b>	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)	3	1035	Percent Change from Baseline in Body Weight	Jan 2028	Feb 2028
<b>NCT07369011</b>	Obstructive Sleep Apnea / Obesity	A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3)	3	800	Percent Change from Baseline in Body Weight and Change from Baseline in Apnea-Hypopnea Index	Mar 2028	Apr 2028
<b>NCT07353931</b>	Osteoarthritis / Overweight	Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4)	3	900	Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score	Mar 2028	May 2028
<b>NCT07392190</b>	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)	3	900	Percent Change from Baseline in Body Weight	Jun 2028	Jul 2028
<b>NCT06603571</b>	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	350	Percent Change from Baseline in Body Weight	Jun 2026	Aug 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Imlunestrant

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT04975308</b>	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	874	Progression-Free Survival (PFS)	Jun 2024	Aug 2027
<b>NCT05514054</b>	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (iDFS)	Oct 2027	Mar 2032
<b>NCT07287098</b>	Breast Neoplasms	A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (preEMBER)	2	600	Percent Change from Baseline in Ki67	Jan 2029	Dec 2029

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Ixekizumab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT06588283</b>	Plaque Psoriasis / Obesity	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	250	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and at Least 10% Weight Reduction	Jan 2026	May 2026
<b>NCT06588296</b>	Psoriatic Arthritis / Obesity	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	279	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Nov 2025	Apr 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Lebrikizumab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05559359</a>	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	367	Proportion of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 16 and a Reduction $\geq 2$ points from Baseline	Jan 2026	Dec 2026
<a href="#">NCT05735483</a>	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	310	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Dec 2027	Apr 2029
<a href="#">NCT06339008</a>	Perennial Allergic Rhinitis	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Sep 2026	Oct 2028
<a href="#">NCT06338995</a>	Chronic Rhinosinusitis With Nasal Polyps	A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	May 2027	Mar 2028
<a href="#">NCT06280716</a>	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (Advance-Asia)	3	301	Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) $\geq 75\%$ Reduction in EASI Score for Mono Cohort	Sep 2025	Aug 2026
<a href="#">NCT06921759</a>	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch)	3	206	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with $\geq 2$ -point Improvement from Baseline	May 2026	Jul 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Lepodisiran

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT06292013</b>	Atherosclerotic Cardiovascular Disease <sup>1</sup>	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	17300	Time to First Occurrence of Any Component of the Major Adverse Cardiovascular Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

<sup>1</sup> Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Mirikizumab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT03519945</b>	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	3	1058	Percentage of Participants in Clinical Remission	Mar 2026	Dec 2027
<b>NCT04232553</b>	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	996	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Apr 2027
<b>NCT05784246</b>	Ulcerative Colitis	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)	3	60	Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders	May 2026	Aug 2026
<b>NCT05509777</b>	Crohn's Disease	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)	3	90	Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52	Dec 2027	Apr 2028
<b>NCT06937099</b>	Crohn's Disease / Obesity	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction	May 2028	May 2028
<b>NCT06937086</b>	Ulcerative Colitis / Obesity	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028
<b>NCT07483099</b>	Crohn's Disease	A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease	2	60	Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response	Jun 2027	Mar 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Mirikizumab (cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07186101</b>	Ulcerative Colitis	LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (TOPAZ-UC)	2	252	Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction	May 2027	Mar 2029
<b>NCT06598943</b>	Ulcerative Colitis	A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	140	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Muvalaplin

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07157774</b>	Elevated Lp(a)	Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a))	3	10450	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2031	Mar 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Olomorasib

Source: *clinicaltrials.gov*, April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT06119581</b>	Carcinoma, Non-Small-Cell Lung	A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)	3	1264	Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE	Nov 2027	Jan 2031
<b>NCT06890598<sup>1</sup></b>	Carcinoma, Non-Small-Cell Lung	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment	May 2029	Feb 2032

<sup>1</sup> Also lists AstraZeneca

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Orforglipron

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT05869903</b>	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3127	Mean Percent Change from Baseline in Body Weight	Jul 2025	Oct 2027
<b>NCT06649045</b>	Obstructive Sleep Apnea / Obesity	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
<b>NCT06672939</b>	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	125	Percent Change from Baseline in Body Mass Index (BMI)	Feb 2027	Mar 2027
<b>NCT06948422</b>	Hypertension	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension)	3	974	Change from baseline in systolic blood pressure	Sep 2027	Sep 2027
<b>NCT07241390</b>	Cardiovascular Disease / Chronic Kidney Disease	A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)	3	7140	Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events	Aug 2031	Aug 2031
<b>NCT07153471</b>	Osteoarthritis	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN)	3	800	Change from Baseline in WOMAC Pain Subscale Score	Apr 2028	May 2028
<b>NCT07223593</b>	Peripheral Artery Disease	Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (ATTAIN-PAD)	3	1205	Percent Change from Baseline in Maximum Walking Distance	Jun 2028	Jun 2028
<b>NCT07202884</b>	Stress Urinary Incontinence / Obesity	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI)	3	1000	Change from Baseline in Incontinence Episode Frequency (IEF)	Mar 2028	Mar 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Orforglipron (cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT06972459</b>	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	3	800	Percent Change from Baseline in Body Weight	Aug 2027	Aug 2027
<b>NCT06972472</b>	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	3	600	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2027	Aug 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Pirtobrutinib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT05023980</b>	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	309	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jul 2025	Oct 2027
<b>NCT05254743</b>	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)	3	662	Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1	Jun 2025	Jan 2028
<b>NCT04666038</b>	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC)	Aug 2023	May 2027
<b>NCT04965493</b>	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2026	Oct 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Pirtobrutinib (cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT04662255</b>	Mantle Cell Lymphoma	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028
<b>NCT07162181</b>	Non-Hodgkin Lymphoma	Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers	2	13	Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events	May 2030	May 2030
<b>NCT06721013</b>	Immune Thrombocytopenia	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1/2	58	Ph. 1 - Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2026	Feb 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Remternetug

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT05463731<sup>1</sup></b>	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	1667	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Apr 2024	May 2026
<b>NCT06653153</b>	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1400	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)	Apr 2029	Oct 2030

<sup>1</sup>CT.gov update in progress

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retatrutide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT05929066</b>	Obesity / Overweight	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2300	Percent Change from Baseline in Body Weight	Apr 2026	May 2026
<b>NCT05929079</b>	Type 2 Diabetes / Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
<b>NCT05882045</b>	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Apr 2026	May 2026
<b>NCT06662383</b>	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight	Dec 2026	Dec 2026
<b>NCT06859268</b>	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	643	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
<b>NCT07035093</b>	Obesity / Chronic Low Back Pain	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)	3	586	Percent Change from Baseline in Body Weight   Change from Baseline in Pain Intensity Per Numeric Rating Scale	Sep 2027	Sep 2027
<b>NCT07232719</b>	Obesity / Overweight	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)	3	250	Percent Change from Baseline in Body Weight	Jul 2027	Jul 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retatrutide (cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07357415</b>	Obesity / Overweight	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)	3	600	Percent Change from Baseline in Body Weight	Oct 2028	Nov 2028
<b>NCT06383390</b>	Atherosclerotic Cardiovascular Disease / CKD	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	3	10000	Time to First Occurrence of Composite Endpoints	Feb 2029	Feb 2029
<b>NCT06260722</b>	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in HbA1c	Aug 2026	Jan 2027
<b>NCT06297603</b>	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in HbA1c	Oct 2026	Nov 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Selpercatinib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT04194944</b>	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Jun 2030
<b>NCT04819100</b>	Non-Small Cell Lung Cancer	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population	Jan 2026	May 2028
<b>NCT04211337</b>	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Nov 2027
<b>NCT03157128</b>	Non-Small Cell Lung Cancer / Medullary Thyroid Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1/2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment	Feb 2025	Feb 2027
<b>NCT03899792</b>	Solid Tumors / CNS Tumors (Pediatric)	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)	1/2	36	Number of Participants With Dose-Limiting Toxicities (DLTs)	Nov 2024	May 2029

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Sofetabart Mipitecan

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<b>NCT07213804</b>	Ovarian Neoplasms	A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)	3	1080	Progression-free Survival (PFS), PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator	Apr 2028	Aug 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Tirzepatide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05556512</a>	Obesity / Overweight	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE) or All-Cause Death	Oct 2027	Oct 2027
<a href="#">NCT06914895</a>	Type 1 Diabetes / Obesity	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1)	3	905	Change from Baseline in HbA1c	Nov 2026	Dec 2026
<a href="#">NCT06962280</a>	Type 1 Diabetes / Obesity	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2)	3	465	Change from Baseline in HbA1c	Nov 2026	Jul 2027
<a href="#">NCT06439277</a>	Obesity (Adolescents)	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2027	Dec 2030
<a href="#">NCT06075667</a>	Obesity / Overweight (Adolescents)	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	3	150	Percent Change from Baseline in Body Mass Index (BMI)	May 2026	Jul 2029
<a href="#">NCT07165028</a>	MASLD	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	3	4500	Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes	Aug 2030	Aug 2032
<a href="#">NCT05536804</a>	Obesity / Chronic Kidney Disease	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D	Sep 2026	Oct 2026
<a href="#">NCT06037252</a>	Type 2 Diabetes / Obesity	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	414	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Early Phase Cardiometabolic Health

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	<a href="#">NCT06643728</a>	Obesity / Overweight	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	240	Percent Change from Baseline in Body Weight	Apr 2026	Jan 2027
GS Insulin Receptor Agonist	<a href="#">NCT07215312</a>	Type 2 Diabetes	A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	2	100	Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)	Nov 2026	Dec 2026
Macupatide	<a href="#">NCT07215559</a>	Obesity / Overweight / T2D	A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	2	200	Percent Change from Baseline in Body Weight	Mar 2027	May 2027
Nisitirostide	<a href="#">NCT06897475</a>	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in HbA1c	Dec 2026	Jan 2027
Naperiglipron	<a href="#">NCT06683508</a>	Obesity / Overweight	A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight	2	288	Percent Change from Baseline in Body Weight	Jan 2026	Sep 2026
NLRP3 INH II	<a href="#">NCT06836232</a>	Recurrent Pericarditis	An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis	2	50	Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation (or Safety and tolerability of VTX2735)	Oct 2026	Oct 2026
Solbinsiran	<a href="#">NCT07269210</a>	Severe Hypertriglyceridemia	A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia	2	60	Change from Baseline in Triglycerides	Mar 2027	Aug 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Early Phase Immunology

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Eltrekibart	<a href="#">NCT06046729</a>	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	352	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Sep 2025	Aug 2026
Zotemtegrast	<a href="#">NCT07415044</a>	Ulcerative Colitis	LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)	2	1431	Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)	Jun 2030	Jul 2031
Zotemtegrast	<a href="#">NCT06226883</a>	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease	2	385	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	Sep 2028	Jun 2030
Zotemtegrast	<a href="#">NCT05611671</a>	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)	2	280	Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Early Phase Neuroscience

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
AT2R Antagonist	<a href="#">NCT07285018</a>	Diabetic Peripheral Neuropathic Pain	A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain	2	150	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jul 2027	Jul 2027
NAV 1.8 INH	<a href="#">NCT07511816</a>	Pain Following Third Molar Removal	A Study of LY4515100 in Participants With Pain Following Third Molar Removal	2	212	Change from Baseline in Self-Reported Pain Intensity	Nov 2026	Dec 2026
Turigrobarb	<a href="#">NCT06568042</a>	Neuropathic Pain	Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	2	588	Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)	Jun 2026	Sep 2026
Mevidalen	<a href="#">NCT06538116</a>	Alzheimer's Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2026	May 2026
Anti-VEGF Gene Therapy	<a href="#">NCT06517888</a>	Vestibular Schwannoma	Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma	1/2	27	AEs with Relationship to the Investigational Medicinal Product and/or to the Administration Procedure (including the Delivery Device)	Aug 2029	Aug 2029
GBA1 Gene Therapy	<a href="#">NCT05487599</a>	Gaucher Disease (Peripheral)	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1/2	15	Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Nov 2031	Nov 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Early Phase Neuroscience (cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GBA1 Gene Therapy	<b>NCT04127578</b>	Parkinson's Disease (GBA1 Mutation)	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1/2	32	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
OTOF Gene Therapy	<b>NCT05821959</b>	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1/2	22	Frequency of Adverse Events	Oct 2028	Oct 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Early Phase Oncology

Source: [clinicaltrials.gov](https://clinicaltrials.gov), April 20, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIPR Agonist LA	<a href="#">NCT07169851</a>	Chemotherapy-Induced Nausea / Vomiting	A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer	2	204	Proportion of Participants With Complete Response (CR) in the Delayed Phase of CINV	Dec 2026	Feb 2027
Tersolisib	<a href="#">NCT05768139</a>	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1)	1/2	720	Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)	Jul 2030	Jul 2030

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.